Literature DB >> 3530649

Captopril effects on pulmonary and systemic hemodynamics in chronic cor pulmonale.

J Zieliński, I Hawrylkiewicz, D Górecka, J Gluskowski, M Kościńska.   

Abstract

A placebo-controlled single-blind study on acute effects of captopril on hypoxic pulmonary hypertension was performed in 15 patients with severe chronic obstructive lung disease recovering from right heart failure. Ten patients received active drug (25 mg captopril orally), five patients received placebo and served as control subjects. Before drug administration, there was no difference in lung function data and pulmonary hemodynamics between patients in both groups. Captopril produced highly significant fall in systemic arterial pressure. No change in breathing frequency, minute ventilation, and pulmonary gas exchange was observed. There was no significant change in studied variables after placebo. The presented data suggest that captopril does not decrease pulmonary vascular resistance in patients with hypoxic pulmonary hypertension. A fall in pulmonary wedge pressure reflects a decrease in left ventricular afterload.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3530649     DOI: 10.1378/chest.90.4.562

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

Review 1.  Should patients have cardiac catheterization prior to long-term oxygen treatment?

Authors:  W MacNee
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 2.  Can pulmonary vasodilators improve survival in cor pulmonale due to hypoxic chronic bronchitis and emphysema?

Authors:  K F Whyte; D C Flenley
Journal:  Thorax       Date:  1988-01       Impact factor: 9.139

3.  Effects of captopril in patients with chronic obstructive pulmonary disease and secondary pulmonary hypertension.

Authors:  D Patakas; D Georgopoulos; H Rodini; P Christaki
Journal:  Postgrad Med J       Date:  1988-03       Impact factor: 2.401

Review 4.  Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy.

Authors:  Chastity N Bradford; Debra R Ely; Mohan K Raizada
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

5.  Comparative effects of angiotensin II on Doppler parameters of left and right heart systolic and diastolic blood flow.

Authors:  B J Lipworth; K D Dagg
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

Review 6.  The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature.

Authors:  R I Cargill; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

7.  ACE and response to pulmonary rehabilitation in COPD: two observational studies.

Authors:  Samantha S C Kon; Caroline J Jolley; Dinesh Shrikrishna; Hugh E Montgomery; James R A Skipworth; Zudin Puthucheary; John Moxham; Michael I Polkey; William D-C Man; Nicholas S Hopkinson
Journal:  BMJ Open Respir Res       Date:  2017-03-08

8.  The renin-angiotensin system and right ventricular structure and function: The MESA-Right Ventricle Study.

Authors:  Corey E Ventetuolo; Joao A C Lima; R Graham Barr; Michael R Bristow; Emilia Bagiella; Harjit Chahal; Jorge R Kizer; David J Lederer; David A Bluemke; Steven M Kawut
Journal:  Pulm Circ       Date:  2012-07       Impact factor: 3.017

9.  Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease.

Authors:  Nicholas W Morrell; Matthew A Higham; Peter G Phillips; B Haleema Shakur; Paul J Robinson; Ray J Beddoes
Journal:  Respir Res       Date:  2005-08-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.